Gujarat Kidney & Super Speciality Ltd
GKSLGujarat Kidney & Super Speciality Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 38% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (24 weeks in) while the P/E sits at the 61st percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +259.7% year on year, and 38% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Gujarat Kidney & Super Speciality Ltd trades at ₹127, in a confirmed uptrend and 24 weeks into that stage. That is +7.8% against its own 200-day average. It sits at 64% of a 52-week range of ₹99 to ₹143. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is in a confirmed uptrend — week 24 of stage 2, confirmed. At ₹127 it trades +7.8% versus its 200-day average and sits at 64% of its 52-week range (₹99–₹143).
Against the market, two honest reads. Cumulative: over the last 7 months the stock moved +24% while the NIFTY 500 moved −2% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Gujarat Kidney & Super Speciality Ltd trades at 64.8× P/E, mid-range by its own standards (61st percentile). Its long-run median P/E is 63.4×, measured across 0.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 64.8× is mid-range by its own standards (61st percentile), against a long-run median of 63.4× measured over 0.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Gujarat Kidney & Super Speciality Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +105.0% | — | — | — |
| Profit | +70.0% | — | — | — |
| EPS | +18.7% | — | — | — |
4-Factor Sector Score
41.3/100 — rank 7 of 7 in Hospitals/Medical Services · 43% evidence confidence · provisional, ranked below fully-evidenced peers
Gujarat Kidney & Super Speciality Ltd scores 41.3 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 7. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 11.4 + 10.4 + 9.5 + 10 = 41.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Gujarat Kidney & Super Speciality Ltd reported ₹30.6 Cr of revenue in the Mar 26 quarter, +212.7% year on year. That is the 3rd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹82.0 Cr. The last four reported quarters add to ₹82.0 Cr.
FY26 revenue came in at ₹82.0 Cr (+105.0% on the year). The latest quarter (Mar 26) printed ₹30.6 Cr, +212.7% year on year — the 3rd consecutive quarter of year-over-year growth.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Gujarat Kidney & Super Speciality Ltd's operating margin is 20.6% in the Mar 26 quarter, −6.1 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 33.0% to 41.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 20.6%, −6.1 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 33.0%–41.0%.
🚨 Why the margin moved: operating margin went −6.1 pp year on year while gross margin went +5.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Gujarat Kidney & Super Speciality Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +259.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹17.0 Cr. That is 15.8% of the quarter's revenue. The same quarter a year earlier earned ₹1.3 Cr.
Mar 26 profit was ₹4.8 Cr, +259.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹17.0 Cr (+70.0%).
Why profit moved: revenue contributed +212.7% and the margin −6.1 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +101.1% vs revenue +115.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 38% of Gujarat Kidney & Super Speciality Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−4.0 Cr of operating cash against ₹17.0 Cr of profit. After ₹103 Cr of capital spending, ₹−107 Cr was left as free cash.
FY26: operating cash of ₹−4.0 Cr against reported profit of ₹17.0 Cr, leaving free cash of ₹−107 Cr after ₹103 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 38% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 38%: the cash cycle tightened 405 days between FY24 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 17.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Gujarat Kidney & Super Speciality Ltd's cash conversion cycle runs −84 days in FY26, down from 321 days in FY24. Capital spending ran ₹137 Cr over the last 3 years. At FY26 sales of ₹82.0 Cr each day of that cycle holds about ₹0.2 Cr, so roughly ₹−19.0 Cr sits inside the business at any moment.
FY26: debtors at 172 days, inventory at 82 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −84 days, tighter than FY24's 321.
The full loop: cash goes out to suppliers and production on day 0; stock waits 82 days to sell; customers pay about 172 days after that; and suppliers themselves are paid at 339 days — netting out to the −84-day cycle.
In money terms: at FY26 sales of ₹82.0 Cr, each day of the cycle holds about ₹0.2 Cr — so the −84-day loop keeps roughly ₹−19.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹137 Cr over the last 3 fiscal years against ₹8.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Gujarat Kidney & Super Speciality Ltd earns a ROCE of 14% in FY26. Return on invested capital clears the cost of that capital by −5.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 20.7% net margin on 0.28× asset turns.
FY26 ROCE is 14%.
🚨 Why the return is what it is — the wiring (FY26): 20.7% net margin × 0.28× asset turns × 1.18× balance-sheet leverage ≈ 6.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 6.5% − 12.0% = a −5.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Gujarat Kidney & Super Speciality Ltd carries total debt of ₹29.0 Cr against shareholder equity of ₹255 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. On the annual view that ratio went from 0.30 in FY25 to 0.11 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹29.0 Cr against shareholder equity of ₹255 Cr — a debt-to-equity of 0.11. On the annual view, debt-to-equity went from 0.30 (FY25) to 0.11 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Gujarat Kidney & Super Speciality Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Gujarat Kidney & Super Speciality Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Unihealth Hospitals LtdUNIHEALTH | 68.3/100Thin evidence · provisional56% evidence | LEADER | 18.8/35 Revenue — · PAT — · OPM change -4 pp 26% evidence | 19.0/25 ROCE 24.5% · OPM 34% 95% evidence | 10.5/20 P/E 46.5× · PEG — 15% evidence | 20.0/20 RS sector 46.5% · RS bench 110.1% · 1Y 346.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 19 + 10.5 + 20 = 68.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Nephrocare Health Services LtdNEPHROPLUS | 53.6/100Thin evidence · provisional52% evidence | BREAKING OUT | 17.6/35 Revenue — · PAT — · OPM change -4 pp 41% evidence | 12.0/25 ROCE 15.3% · OPM 19% 100% evidence | 14.0/20 P/E 91.5× · PEG 0.04 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 17.6 + 12 + 14 + 10 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Dr Agarwals Health Care LtdAGARWALEYE | 50.3/100Mixed-positive evidence69% evidence | TURNING | 27.1/35 Revenue 21.6% · PAT 52.7% · OPM change 1 pp 95% evidence | 9.2/25 ROCE 11.1% · OPM 29% 76% evidence | 8.5/20 P/E 114× · PEG — 15% evidence | 5.5/20 RS sector -38.8% · RS bench 0% · 1Y 4.3%7 of 11 weeks ahead 70% evidence |
| Exact sum: 27.1 + 9.2 + 8.5 + 5.5 = 50.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -38.8% and the one-year return is 4.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4KRM Ayurveda LtdKRMAYURVED | 57.7/100Thin evidence · provisional34% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 12 pp 19% evidence | 18.1/25 ROCE 35.3% · OPM 33% 95% evidence | 11.5/20 P/E 29× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 18.1 + 18.1 + 11.5 + 10 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Gaudium IVF and Women Health LtdGAUDIUMIVF | 56.2/100Thin evidence · provisional40% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 7.7 pp 39% evidence | 17.8/25 ROCE 29.3% · OPM 40.1% 95% evidence | 11.0/20 P/E 40.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 17.4 + 17.8 + 11 + 10 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Park Medi World LtdPARKHOSPS | 53.5/100Thin evidence · provisional33% evidence | BREAKING OUT | 18.7/35 Revenue — · PAT — · OPM change 3 pp 32% evidence | 14.8/25 ROCE 19.3% · OPM 28% 76% evidence | 10.0/20 P/E 49× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 18.7 + 14.8 + 10 + 10 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Gujarat Kidney & Super Speciality Ltdthis pageGKSL | 41.3/100Thin evidence · provisional43% evidence | FADING | 11.4/35 Revenue — · PAT — · OPM change -6.1 pp 45% evidence | 10.4/25 ROCE 14.5% · OPM 20.6% 95% evidence | 9.5/20 P/E 64.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 11.4 + 10.4 + 9.5 + 10 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Gujarat Kidney & Super Speciality Ltd's share price today?
Gujarat Kidney & Super Speciality Ltd trades at ₹127. The company is valued at ₹1,004 Cr. The stock sits at 64% of its 52-week range of ₹99–₹143, +7.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 24 weeks in. — as of 31 July 2026.
What were Gujarat Kidney & Super Speciality Ltd's latest quarterly results?
Gujarat Kidney & Super Speciality Ltd reported revenue of ₹30.6 Cr and net profit of ₹4.8 Cr for the Mar 26 quarter. Revenue rose 212.7% and profit rose 259.7% year on year. Earnings per share were ₹0.64. The operating margin was 20.6%, 6.1 pp lower than a year earlier. — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's revenue?
Gujarat Kidney & Super Speciality Ltd reported revenue of ₹30.6 Cr in the Mar 26 quarter, +212.7% year on year. For the full FY26 fiscal year, revenue was ₹82.0 Cr (+105.0%). — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's profit?
Gujarat Kidney & Super Speciality Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +259.7% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹17.0 Cr. The operating margin ran 20.6% in the latest quarter. — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's market cap?
Gujarat Kidney & Super Speciality Ltd's market capitalisation is ₹1,004 Cr at a share price of ₹127. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's P/E ratio?
Gujarat Kidney & Super Speciality Ltd trades at a P/E of 64.8×, at the 61st percentile of its own 1-year range, against a long-run median of 63.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Gujarat Kidney & Super Speciality Ltd pay a dividend?
No — Gujarat Kidney & Super Speciality Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd overvalued?
On its own history, Gujarat Kidney & Super Speciality Ltd looks mid-range against its own history: its P/E of 64.8× sits at the 61st percentile of its 1-year range (long-run median 63.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd growing?
Yes — Gujarat Kidney & Super Speciality Ltd is growing: latest-quarter revenue +212.7% year on year, profit +259.7%, and the margin −6.1 pp at 20.6%. The earnings engine currently reads: improving — as of 31 July 2026.
How is Gujarat Kidney & Super Speciality Ltd performing?
Gujarat Kidney & Super Speciality Ltd is in a confirmed uptrend, 24 weeks in. Its latest quarter's revenue rose 212.7% and profit rose 259.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 6 weeks. — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 24 of stage 2), trading +7.8% versus its 200-day average and at 64% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd beating the market?
Not lately — on a trailing-13-week view Gujarat Kidney & Super Speciality Ltd is currently behind the NIFTY 500 (6 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7 months the stock moved +24% against the NIFTY 500's −2% — ahead of the index over the full window. — as of 31 July 2026.
Will Gujarat Kidney & Super Speciality Ltd's share price go up?
This page publishes no price forecast for Gujarat Kidney & Super Speciality Ltd. What it measures instead: the share price is ₹127, the price is in a confirmed uptrend 24 weeks in. Its P/E of 64.8× sits at the 61st percentile of its own 1-year range. — as of 31 July 2026.
Who owns Gujarat Kidney & Super Speciality Ltd?
Promoters hold 71.5% of Gujarat Kidney & Super Speciality Ltd, foreign institutions 4.9%, domestic institutions 0.6% and the public 23.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Gujarat Kidney & Super Speciality Ltd have too much debt?
No — Gujarat Kidney & Super Speciality Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 14×. FY26 borrowings were ₹29.0 Cr against equity of ₹253 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's capex?
Gujarat Kidney & Super Speciality Ltd spent ₹137 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹103 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Gujarat Kidney & Super Speciality Ltd's cash flow?
Gujarat Kidney & Super Speciality Ltd generated ₹−4.0 Cr of operating cash flow in FY26 and ₹−107 Cr of free cash flow after ₹103 Cr of capital spending. Reported profit that year was ₹17.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 38% of Gujarat Kidney & Super Speciality Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−4.0 Cr against reported profit of ₹17.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Gujarat Kidney & Super Speciality Ltd in its business cycle?
Gujarat Kidney & Super Speciality Ltd's FY26 operating margin was 33.0%, against a 3-year band of 33.0%–41.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 20.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Gujarat Kidney & Super Speciality Ltd story?
The sharpest disagreement: profits are rising, but only 38% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Gujarat Kidney & Super Speciality Ltd a stock worth studying right now?
This is not investment advice. The machine read: Gujarat Kidney & Super Speciality Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.